



MAIL STOP
AMENDMENT

ifn

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: J.M. Nuss et al. Attorney Docket No.: CHIR122036
Application No.: 10/719,896 Group Art Unit: 1614
Filed: November 21, 2003
Title: SMALL MOLECULE PI 3-KINASE INHIBITORS
AND METHODS OF THEIR USE

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

May 17, 2004

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. Copies of the listed publications, and other information are enclosed for the Examiner's use.
2. Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.
3. Pursuant to 37 C.F.R. § 1.704(d), this Information Disclosure Statement is accompanied by a statement that each item of information contained in this Information Disclosure statement was cited in a communication from a foreign patent office in a counterpart application. Such communication was received by an individual designated in 37 C.F.R. § 1.56(c) on April 21, 2004, which is not more than thirty days prior to the filing of this Information Disclosure Statement.
4. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

appropriate length required upon the filing of any reply during the entire prosecution of this application.

Respectfully submitted,



CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}



George E. Renzoni, Ph.D.
Registration No. 37,919
Direct Dial No. 206.695.1755

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date:



GER:md

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



MAIL STOP
AMENDMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: J.M. Nuss et al.

Attorney Docket No.: CHIR122036

Application No.: 10/719,896

Group Art Unit: 1614

Filed: November 21, 2003

Examiner:

Title: SMALL MOLECULE PI 3-KINASE INHIBITORS
AND METHODS OF THEIR USE

CERTIFICATION STATEMENT UNDER 37 C.F.R. § 1.97(e) AND/OR § 1.704(d)

Seattle, Washington 98101

May 17, 2004

TO THE COMMISSIONER FOR PATENTS:

1. I, the person signing below, state that each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.
2. I, the person signing below, am the attorney or agent who prepared or prosecuted the application, signing on the basis of the information in my file.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}

George E. Renzoni, Ph.D.
Registration No. 37,919

Direct Dial No. 206.695.1755

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below date.

Date: May 17, 2004

GER:md

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



INFORMATION CITED BY APPLICANT(S) THAT MAY BE MATERIAL TO THE PROSECUTION OF THE SUBJECT APPLICATION

Applicant: J.M. Nuss et al. Attorney Docket No. CHIR122036

Application No.: 10/719,896 Group Art Unit: 1614

Filed: November 21, 2003

Title: SMALL MOLECULE PI 3-KINASE INHIBITORS
AND METHODS OF THEIR USE

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document No.	Kind Code	Date (mm/dd/yyyy)	Name
	U1	3,975,384	A	08/17/1976	Narr et al.

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	Document No.	Kind Code	Publication Date (mm/dd/yyyy)	Country	English Abstract Provided	Translation Provided
	F1	EP 0459 830	A1	12/04/1991	EP		
	F2	WO 01/72745	A1	10/04/2001	WO		
	F3	WO 01/83456	A1	11/08/2001	WO		X
	F4	WO 02/22608	A1	03/21/2002	WO		
	F5	WO 02/062789	A1	08/15/2002	WO		
	F6	WO 02/102313	A2	12/27/2002	WO		
	F7	EP 1 277 738	A1	01/22/2003	EP		
	F8	WO 03/030909	A1	04/17/2003	WO		

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

OTHER INFORMATION
(Including Author, Title, Date, Pertinent Pages, Etc.)

<u>*Examiner</u>	<u>Cite</u>
<u>Initial</u>	<u>No.</u>
	O1 Brown, D.M., and George A.R. Kon, "Some Heterocyclic Analogues of Stilbenes," <i>J. Chem. Soc.</i> :2147-2153, 1948.
	O2 Bundy, G.L., et al., "Synthesis of 2,4-Diaminopyrrolo[2,3- <i>d</i>]Pyrimidines <i>Via</i> Thermal Fischer Indolization. Pyrazole Formation with Ytterbium Triflate Catalysis," <i>J. Heterocyclic Chem.</i> 37:1471-1477, Nov.-Dec. 2000.
	O3 Bundy, G.L., et al., "Synthesis of Novel 2,4-Diaminopyrrolo[2,3- <i>d</i>]Pyrimidines With Antioxidant, Neuroprotective, and Antiasthma Activity," <i>J. Med. Chem.</i> 38:4161-4163, 1995.
	O4 Cabaj, J.E., et al., "Bromine-Mediated Addition of Nucleophiles to the Electron-Rich Pyrimidine Subunit of Tirilazad," <i>J. Org. Chem.</i> 59:5090-5092, 1994.
	O5 Kowalewski, A., et al., "Unfused Hetrobicycles as Amplifiers of Phleomycin. IV 4,5'-Bipyrimidines with Dimethylamino and/or Dimethylaminoethylamino Substituents," <i>Aust. J. Chem.</i> 34(12):2929-2933, 1981.
	O6 Ouf, A.A. Abou, et al., "Preparation of Some Methyl Pyrimidines Expected to be Antimetabolites," <i>Egypt J. Pharm. Sci.</i> 14(2):180-195, 1973.

<u>Examiner</u>	<u>Date Considered</u>

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GER:md

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100